Sarepta are in a world of pain now.
Gene Therapy was always a 7 to 10 year dream...back to the drawing board.
They still need to provide the FDA with efficacy data for Exondys, their only commercial product...otherwise that's gonski too!
Exondys brings in circa US$400m revenue and only applicable for 13% of DMD boys.
Combination trial with ATL1102 is on the cards...PUL2 efficacy data will romp it in for Sarepta.
They have a +US1.5B cash war chest...interesting times.
Sarepta gene therapy study missed key target in Duchennes, page-6
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.003(3.90%) |
Mkt cap ! $74.82M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 8.3¢ | 7.9¢ | $110.5K | 1.369M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 21322 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.2¢ | 169303 | 3 |
View Market Depth
| Last trade - 15.26pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.0¢ |
Change
0.003 ( 3.90 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.3¢ | 7.9¢ | 105021 | ||
| Last updated 15.55pm 08/05/2024 ? | |||||
| PER (ASX) Chart |